James Smith - Pfizer Independent Director

<div class='circular--portrait' style='background:#FCD202;color: white;font-size:3em;padding-top: 40px;;'>PFE</div>
PFE -- USA Stock  


Mr. James Clifton Smith is an Independent Director of Pfizer Inc. Mr. Smith is President and Chief Executive Officer and Director of Thomson Reuters Corporationrationration, a provider of intelligent information for businesses and professionals, since January 2012 and its Chief Operating Officer from September 2011 to December 2011 and Chief Executive Officer, Thomson Reuters Professional Division, from 2008 to 2011. Prior to the acquisition of Reuters Group PLC by The Thomson Corporationrationration in 2008, served as Chief Operating Officer of Thomson and as President and Chief Executive Officer of Thomson Learnings Academic and Reference Group. Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council. Mr. Smiths experience as President and CEO of Thomson Reuters brings valuable leadership, finance, international business, talent and management skills to our Board. Pfizer benefits from Mr. Smiths organizational expertise and leadership experience, honed in numerous senior management roles and on notable merger and acquisition activity, including the acquisition and subsequent integration of two of the information industrys preeminent firms, as well as his strong operational and international expertise
Age: 58  Director Since 2014      
212 733-2323  www.pfizer.com
Smith?s previous experience running global Human Resources for the Thomson Corporationrationrationration informs his strong advocacy for culture and talent development.

James Smith Latest Insider Activity

Management Efficiency

The company has 47.96 B in debt with debt to equity (D/E) ratio of 80.0 . This implies that the company may be unable to create cash to meet all of its financial commitments. Pfizer has Current Ratio of 1.44 which is typical for the industry and considered as normal.

Similar Executives

Showing few of many executives


Ronald TaylorAllergan Plc
Lynn ElsenhansGlaxoSmithKline PLC
Hubert JolyJohnson Johnson
Ron TaylorAllergan Plc
Sherilyn McCoyAstrazeneca PLC
Vindi BangaGlaxoSmithKline PLC
Robert BertoliniBristol Myers Squibb Company
Ellen MarramEli Lilly And Company
Carolyn BertozziEli Lilly And Company
Tim JacksonSmithAstrazeneca PLC
Lewis CampbellBristol Myers Squibb Company
Karen VousdenBristol Myers Squibb Company
Erik FyrwaldEli Lilly And Company
Michael GreenbergAllergan Plc
Daniel PodolskyGlaxoSmithKline PLC
Charles PrinceJohnson Johnson
William HarrisonMerck Company
Stacey CartwrightGlaxoSmithKline PLC
James BloemAllergan Plc
Frans HoutenNovartis AG
Ian DavisJohnson Johnson

Company Summary

Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 88300 people.Pfizer (PFE) is traded on BATS Exchange in USA. It is located in 235 East 42nd Street, New York, NY 10017, United States and employs 88,300 people. Pfizer is listed under Pharmaceutical Products category by Fama And French industry classification.

Pfizer Leadership Team

John Young, Group President - Pfizer Innovative Health and Angela HwangView
Jennifer Damico, Senior Vice President Principal Accounting Officer, ControllerView
Frank DAmelio, Chief Financial Officer, Executive Vice President - Business Operations and Global SupplyView
Douglas Lankler, Executive Vice President General CounselView
Dawn Rogers, Chief Human Resource Officer, Executive Vice PresidentView
Helen Hobbs, Independent DirectorView
Shantanu Narayen, Lead Independent DirectorView
James Smith, Independent DirectorView
Dennis Ausiello, Independent DirectorView
Mikael Dolsten, Chief Scientific Officer, President - Worldwide Research, Development and MedicalView
Frances Fergusson, Independent DirectorView
Stephen Sanger, Independent DirectorView
Lidia Fonseca, Executive Vice President, Chief Technology Officer and Digital OfficerView
Gordon Loh, Senior Vice President Corporate AuditView
Wyllie Cornwell, Independent DirectorView
Suzanne Johnson, Independent DirectorView
Alexander Mackenzie, Executive Vice President Chief Development OfficerView
Geno Germano, Group President of Global Innovative Pharma Bus.View
Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial OperationsView
Sally Susman, Chief Corporate Affairs Officer, Executive Vice PresidentView
Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global SupplyView
Susan Hockfield, Independent DirectorView
Freda LewisHall, Executive Vice President Chief Medical OfficerView
Rady Johnson, Chief Compliance, Quality and Risk Officer, Executive Vice PresidentView
Dan Littman, Independent DirectorView
Ian Read, Chairman, CEO and Chairman of Executive CommitteeView
James Kilts, Independent DirectorView
Don Cornwell, Independent DirectorView
James Quincey, Independent DirectorView
Charles Hill, Executive Vice President - Worldwide Human ResourcesView
Joseph Echevarria, Independent DirectorView
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare BusinessView
Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global SupplyView
Angela Hwang, Group President, Pfizer Biopharmaceuticals GroupView
Scott Gottlieb, Independent DirectorView
Ronald Blaylock, Independent DirectorView
Kathrin Jansen, Senior Vice President - Vaccine Research & DevelopmentView
Michael Goettler, Group President - Pfizer UpjohnView

Stock Performance Indicators

Current Sentiment - PFE

Pfizer Investor Sentiment

Predominant part of Macroaxis users are at this time bullish on Pfizer. What is your perspective on investing in Pfizer? Are you bullish or bearish?
98% Bullish
2% Bearish

Currently Active Assets on Macroaxis

Purchased over 100 shares of
few days ago
Traded for 2.34
Purchased over 70 shares of
few days ago
Traded for 42.57
Purchased over 100 shares of
few days ago
Traded for 25.97
Purchased few shares of
few days ago
Traded for 161.56
Purchased over 20 shares of
few days ago
Traded for 115.74
Please check Your Equity Center. Please also try Money Flow Index module to determine momentum by analyzing money flow index and other technical indicators.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page